Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)

Giovanna Fabio, Francesca Minonzio, Paola Delbini, Annamaria Bianchi, Maria Domenica Cappellini

Research output: Contribution to journalArticlepeer-review

Abstract

Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically heterogeneous. In JH, symptomatic organ involvement occurs as early as the second decade of life. Heart failure and/or arrhythmias are the most frequent causes of death. Phlebotomy is the safest, most effective, and most economic therapeutic approach in hemochromatosis patients but is not indicated during the treatment of severe congestive heart failure with unstable hemodynamic status. The treatment of iron overload in these prohibitive clinical situations has to be carried out using iron chelators. We report a case of heart failure in the setting of unrecognized juvenile hemochromatosis successfully treated by the simultaneous administration of deferoxamine and deferiprone. To our knowledge, this is the first patient affected by JH treated with combined chelation regimen.

Original languageEnglish
Pages (from-to)362-364
Number of pages3
JournalBlood
Volume109
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)'. Together they form a unique fingerprint.

Cite this